Illumina, Inc. (ILMN), a major developer of life science tools for large-scale genetic analysis, has launched MiSeq FGx Forensic Genomics System, the first fully approved next-generation (NGS) system specifically for forensic genomic applications. This has definitely raised the company's value in the forensic DNA analysis space.
This new system has the ability to examine short tandem repeats (STR) along with other valuable genetic markers all at the same time, thereby enabling scientists to perform a more robust analysis of a particular DNA sample compared to previous technology. This, in turn, provides a more reliable analysis of both routine as well as challenging forensic samples.
This sample-to-answer solution, an advance version of Illumina's renowned MiSeq next generation sequencer, incorporates the MiSeq FGx DNA sequencer, ForenSeq DNA Signature Prep Kit and ForenSeq Universal Analysis Software.
The MiSeq FGx DNA sequencer enjoys the advantage of llumina's sequencing by synthesis (SBS) technology, which offers a massively parallel approach for sequencing large numbers of PCR amplicons.
On the other hand, using low amounts of DNA, the ForenSeq Prep kit enables scientists to amplify the genetic information derived from a sample performing only a single test. The intuitive ForenSeq software is used to analyze and interpret a wide range of forensics casework and database samples and delivers reports on a stand-alone, dedicated server.
Notably, this system will not only play a crucial role in solving criminal caseworks but also hold immense value in other unusual situations like mass disasters, missing persons, and unidentified human remains.
Management expects the MiSeq FGx System to help reduce the huge backlog in investigative samples, and thus facilitate solutions in cold cases. We believe these positives will reduce the investigation costs of investigating agencies and in turn, propel demand for the installation of this system.
In its last reported quarter's financial results, demand for Illumina's MiSeq continued to outperform the company's expectations. We expect this trend to continue in the ongoing quarter as well given the significant utility of the MiSeq FGx system.
Currently, Illumina has a Zacks Rank #2 (Buy). Better-ranked stocks in the med-biomed/generic industry include Alexion Pharmaceuticals, Inc. (ALXN), Five Prime Therapeutics, Inc. (FPRX) and NewLink Genetics Corp. (NLNK). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment